Top

Acta Diabetologica

Published in:

01-12-2016 | Original Article

Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus

Authors: Hui Ning, Hong Tao, Zhanping Weng, Xingbo Zhao

Published in: Acta Diabetologica | Issue 6/2016

Abstract

Aims

Fatty acid-binding protein 4 (FABP4) is mainly expressed in adipocytes and macrophages and is demonstrated to be elevated in diabetes patients. The aim of this study was to evaluate the possible role of FABP4 in the diagnosis of GDM and to investigate the relationship between FABP4 and overweight, insulin resistance and inflammatory marker TNF-α.

Methods

A total of 46 women with GDM and 55 age-matched pregnant women without GDM (non-GDM) were eligible for the study. Demographic and biochemical parameters and fasting venous blood samples of two groups were collected from all cases. Serum concentrations of FABP4 were determined using enzyme-linked immunosorbent assay (ELISA). The predictive value of Serum FABP4 level was evaluated using receiver operating characteristic curve (ROC curve) analysis.

Results

We found that the serum FABP4 levels were significantly higher in GDM compared to the non-GDM group. The area under the ROC curve assay yielded a satisfactory result of 0.94 (95 % confidence interval 0.90–0.98; p < 0.001). The best compromise between 86.96 % specificity and 89.09 % sensitivity was obtained with a cutoff value of 1.96 ng/mL for GDM diagnosis. Moreover, a significant positive correlation was observed between FABP4 and overweight, insulin resistance and TNF-α in pregnant women with GDM.

Conclusions

These results suggest that serum FABP4 may potentially serve as a novel biomarker for the prediction of GDM.

Group HSCR, Metzger BE, Lowe LP et al (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991–2002. doi:10.1056/NEJMoa0707943 CrossRef

Ben-Haroush A, Yogev Y, Hod M (2004) Epidemiology of gestational diabetes mellitus and its association with type 2 diabetes. Diabet Med 21:103–113CrossRefPubMed

El-Chaar D, Finkelstein SA, Tu X et al (2013) The impact of increasing obesity class on obstetrical outcomes. J Obstet Gynaecol Can 35:224–233CrossRefPubMed

Kim SY, Saraiva C, Curtis M, Wilson HG, Troyan J, Sharma AJ (2013) Fraction of gestational diabetes mellitus attributable to overweight and obesity by race/ethnicity, California, 2007–2009. Am J Public Health 103:e65–e72. doi:10.2105/AJPH.2013.301469 CrossRefPubMedPubMedCentral

Boney CM, Verma A, Tucker R, Vohr BR (2005) Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 115:e290–e296. doi:10.1542/peds.2004-1808 CrossRefPubMed

Crowther CA, Hiller JE, Moss JR (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352:2477–2486. doi:10.1056/NEJMoa042973 CrossRefPubMed

Yogev Y, Chen R, Hod M et al (2010) Hyperglycemia and adverse pregnancy outcome (HAPO) study: preeclampsia. Am J Obstet Gynecol 202(255):e251–e257. doi:10.1016/j.ajog.2010.01.024 CrossRef

Fang P, Shi M, Yu M, Guo L, Bo P, Zhang Z (2014) Endogenous peptides as risk markers to assess the development of insulin resistance. Peptides 51:9–14. doi:10.1016/j.peptides.2013.10.025 CrossRefPubMed

Hunt CR, Ro JH, Dobson DE, Min HY, Spiegelman BM (1986) Adipocyte P2 gene: developmental expression and homology of 5′-flanking sequences among fat cell-specific genes. Proc Natl Acad Sci USA 83:3786–3790CrossRefPubMed

10.

Spiegelman BM, Frank M, Green H (1983) Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem 258:10083–10089PubMed

11.

Baxa CA, Sha RS, Buelt MK et al (1989) Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry 28:8683–8690CrossRefPubMed

12.

Amri EZ, Bertrand B, Ailhaud G, Grimaldi P (1991) Regulation of adipose cell differentiation I. Fatty acids are inducers of the aP2 gene expression. J Lipid Res 32:1449–1456PubMed

13.

Melki SA, Abumrad NA (1993) Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J Lipid Res 34:1527–1534PubMed

14.

Xu A, Wang Y, Xu JY et al (2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52:405–413. doi:10.1373/clinchem.2005.062463 CrossRefPubMed

15.

Xu A, Tso AW, Cheung BM et al (2007) Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 115:1537–1543. doi:10.1161/CIRCULATIONAHA.106.647503 CrossRefPubMed

16.

Tso AW, Xu A, Sham PC et al (2007) Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 30:2667–2672. doi:10.2337/dc07-0413 CrossRefPubMed

17.

Ota H, Furuhashi M, Ishimura S et al (2012) Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 25:1124–1130. doi:10.1038/ajh.2012.88 CrossRefPubMedPubMedCentral

18.

Baessler A, Lamounier-Zepter V, Fenk S et al (2014) Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects. Nutr Diabetes 4:e106. doi:10.1038/nutd.2014.3 CrossRefPubMedPubMedCentral

19.

Fuseya T, Furuhashi M, Yuda S et al (2014) Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol 13:126. doi:10.1186/s12933-014-0126-7 CrossRefPubMedPubMedCentral

20.

Reiser H, Klingenberg R, Hof D et al (2015) Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler Thromb Vasc Biol 35:1872–1879. doi:10.1161/ATVBAHA.115.305365 CrossRefPubMed

21.

Parra S, Cabre A, Marimon F et al (2014) Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients. Lupus 23:245–254. doi:10.1177/0961203313517405 CrossRefPubMed

22.

Djousse L, Gaziano JM (2012) Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes. Lipids 47:757–762. doi:10.1007/s11745-012-3689-7 CrossRefPubMedPubMedCentral

23.

Li YY, Xiao R, Li CP, Huangfu J, Mao JF (2015) Increased plasma levels of FABP4 and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus. Med Sci Monit 21:426–431. doi:10.12659/MSM.892431 CrossRefPubMedPubMedCentral

24.

International Association of D, Pregnancy Study Groups Consensus P, Metzger BE et al (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676–682. doi:10.2337/dc09-1848 CrossRef

25.

Hartling L, Dryden DM, Guthrie A et al. (2012) Screening and diagnosing gestational diabetes mellitus. Evid Rep Technol Assess (Full Rep) 12:1–327

26.

Agarwal MM (2015) Gestational diabetes mellitus: an update on the current international diagnostic criteria. World J Diabetes 6:782–791. doi:10.4239/wjd.v6.i6.782 CrossRefPubMedPubMedCentral

27.

Kohler M, Ziegler AG, Beyerlein A (2015) Development of a simple tool to predict the risk of postpartum diabetes in women with gestational diabetes mellitus. Acta Diabetol. doi:10.1007/s00592-015-0814-0 PubMedCrossRef

28.

Zhao C, Wang F, Wang P, Ding H, Huang X, Shi Z (2015) Early second-trimester plasma protein profiling using multiplexed isobaric tandem mass tag (TMT) labeling predicts gestational diabetes mellitus. Acta Diabetol 52:1103–1112. doi:10.1007/s00592-015-0796-y CrossRefPubMed

29.

He X, de Seymour JV, Sulek K et al (2016) Maternal hair metabolome analysis identifies a potential marker of lipid peroxidation in gestational diabetes mellitus. Acta Diabetol 53:119–122. doi:10.1007/s00592-015-0737-9 CrossRefPubMed

30.

Bhavadharini B, Mahalakshmi MM, Maheswari K et al (2016) Use of capillary blood glucose for screening for gestational diabetes mellitus in resource-constrained settings. Acta Diabetol 53:91–97. doi:10.1007/s00592-015-0761-9 CrossRefPubMed

31.

Megia A, Gil-Lluis P, Naf S et al (2015) Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth. Acta Diabetol 52:693–700. doi:10.1007/s00592-014-0705-9 CrossRefPubMed

32.

Cabre A, Lazaro I, Girona J et al (2008) Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 49:1746–1751. doi:10.1194/jlr.M800102-JLR200 CrossRefPubMed

33.

Rhee EJ, Lee WY, Park CY et al (2009) The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160:165–172. doi:10.1530/EJE-08-0665 CrossRefPubMed

34.

Biron-Shental T, Schaiff WT, Ratajczak CK, Bildirici I, Nelson DM, Sadovsky Y (2007) Hypoxia regulates the expression of fatty acid-binding proteins in primary term human trophoblasts. Am J Obstet Gynecol 197(516):e511–e516. doi:10.1016/j.ajog.2007.03.066 CrossRef

35.

Makkar A, Mishima T, Chang G, Scifres C, Sadovsky Y (2014) Fatty acid binding protein-4 is expressed in the mouse placental labyrinth, yet is dispensable for placental triglyceride accumulation and fetal growth. Placenta 35:802–807. doi:10.1016/j.placenta.2014.07.008 CrossRefPubMedPubMedCentral

36.

Nourani MR, Owada Y, Kitanaka N et al (2005) Occurrence of immunoreactivity for adipocyte-type fatty acid binding protein in degenerating granulosa cells in atretic antral follicles of mouse ovary. J Mol Histol 36:491–497. doi:10.1007/s10735-006-9024-y CrossRefPubMed

37.

Fasshauer M, Seeger J, Waldeyer T et al (2008) Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens 21:582–586. doi:10.1038/ajh.2008.23 CrossRefPubMed

38.

Shangguan X, Liu F, Wang H, He J, Dong M (2009) Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta 407:58–61. doi:10.1016/j.cca.2009.06.031 CrossRefPubMed

39.

Scifres CM, Catov JM, Simhan H (2012) Maternal serum fatty acid binding protein 4 (FABP4) and the development of preeclampsia. J Clin Endocrinol Metab 97:E349–E356. doi:10.1210/jc.2011-2276 CrossRefPubMed

40.

Di Cianni G, Lencioni C, Volpe L et al (2007) C-reactive protein and metabolic syndrome in women with previous gestational diabetes. Diabetes Metab Res Rev 23:135–140. doi:10.1002/dmrr.661 CrossRefPubMed

41.

Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW (2005) Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 90:3983–3988. doi:10.1210/jc.2004-2494 CrossRefPubMed

42.

Winzer C, Wagner O, Festa A et al (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–1727CrossRefPubMed

43.

Fakhrzadeh H, Alatab S, Sharifi F et al (2012) Carotid intima media thickness, brachial flow mediated dilation and previous history of gestational diabetes mellitus. J Obstet Gynaecol Res 38:1057–1063. doi:10.1111/j.1447-0756.2011.01829.x CrossRefPubMed

44.

Baeten JM, Bukusi EA, Lambe M (2001) Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health 91:436–440CrossRefPubMedPubMedCentral

45.

Sebire NJ, Jolly M, Harris JP et al (2001) Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 25:1175–1182. doi:10.1038/sj.ijo.0801670 CrossRefPubMed

46.

Kim SY, Sappenfield W, Sharma AJ et al (2013) Racial/ethnic differences in the prevalence of gestational diabetes mellitus and maternal overweight and obesity, by nativity, Florida, 2004-2007. Obesity (Silver Spring) 21:E33–E40. doi:10.1002/oby.20025 CrossRef

47.

Kim C, Newton KM, Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25:1862–1868CrossRefPubMed

48.

Aye IL, Lager S, Ramirez VI et al (2014) Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod 90:129. doi:10.1095/biolreprod.113.116186 CrossRefPubMedPubMedCentral

49.

Kleiblova P, Dostalova I, Bartlova M et al (2010) Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Mol Cell Endocrinol 314:150–156. doi:10.1016/j.mce.2009.08.002 CrossRefPubMed

50.

Hauguel-de Mouzon S, Guerre-Millo M (2006) The placenta cytokine network and inflammatory signals. Placenta 27:794–798. doi:10.1016/j.placenta.2005.08.009 CrossRefPubMed

51.

Jansson N, Rosario FJ, Gaccioli F et al (2013) Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies. J Clin Endocrinol Metab 98:105–113. doi:10.1210/jc.2012-2667 CrossRefPubMed

52.

Jansson T, Ekstrand Y, Bjorn C, Wennergren M, Powell TL (2002) Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. Diabetes 51:2214–2219CrossRefPubMed

53.

Jones HN, Jansson T, Powell TL (2009) IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2. Am J Physiol Cell Physiol 297:C1228–C1235. doi:10.1152/ajpcell.00195.2009 CrossRefPubMed

54.

Jones HN, Woollett LA, Barbour N, Prasad PD, Powell TL, Jansson T (2009) High-fat diet before and during pregnancy causes marked up-regulation of placental nutrient transport and fetal overgrowth in C57/BL6 mice. FASEB J 23:271–278. doi:10.1096/fj.08-116889 CrossRefPubMedPubMedCentral

55.

Pantham P, Aye IL, Powell TL (2015) Inflammation in maternal obesity and gestational diabetes mellitus. Placenta 36:709–715. doi:10.1016/j.placenta.2015.04.006 CrossRefPubMedPubMedCentral

56.

Furuhashi M, Hiramitsu S, Mita T et al (2015) Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. J Lipid Res 56:2372–2380. doi:10.1194/jlr.M059469 CrossRefPubMedPubMedCentral

57.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415. doi:10.1172/JCI117936 CrossRefPubMedPubMedCentral

58.

Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907–2910. doi:10.1210/jcem.83.8.5026 PubMedCrossRef

59.

Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327–332CrossRefPubMed

60.

Cao H, Sekiya M, Ertunc ME et al (2013) Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 17:768–778. doi:10.1016/j.cmet.2013.04.012 CrossRefPubMedPubMedCentral

61.

Phillips CM, Perry IJ (2013) Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab 98:E1610–E1619. doi:10.1210/jc.2013-2038 CrossRefPubMed

62.

Furuhashi M, Ishimura S, Ota H, Miura T (2011) Lipid chaperones and metabolic inflammation. Int J Inflam 2011:642612. doi:10.4061/2011/642612 CrossRefPubMedPubMedCentral

Title: Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus
Authors: Hui Ning
Hong Tao
Zhanping Weng
Xingbo Zhao
Publication date: 01-12-2016
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 6/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-016-0867-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2016

Acute-phase proteins and incidence of diabetes: a population-based cohort study

Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy

Statin-induced improvements in vulnerable plaques are attenuated in poorly controlled diabetic patients with coronary atherosclerosis disease: a serial optical coherence tomography analysis

Muscle dysfunction in type 2 diabetes: a major threat to patient’s mobility and independence

Sex ratio at birth is associated with type 1 diabetes characteristics

Blood levels of pro-inflammatory and anti-inflammatory cytokines in a patient with a flat glucose curve

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage